FDA labels Abbott’s recall of HeartMate II, HeartMate 3 LVAS as Class I

The FDA has identified this as a Class I recall, the most serious type of recall. Use of these devices may cause serious injuries or death.

Recalled product

• Product Names: HeartMate II and HeartMate 3 Left Ventricular Assist System (LVAS)
• Product Codes: DSQ
  • Class 1 Device Recall HeartMate II Left Ventricular Assist System (fda.gov)
  • Class 1 Device Recall HeartMate 3 Left Ventricular Assist System (fda.gov)
• Model Numbers: Full List of Affected Devices
• Distribution Dates: Starting in April 21, 2008
• Devices Recalled in the U.S.: 13,883
• Date Initiated by Firm: February 19, 2024

Device use
The HeartMate II and HeartMate 3 Left Ventricular Assist Systems (LVAS) are used to help the heart pump blood when it’s not able to do so effectively on its own.

The HeartMate II and 3 are used for both short- and long-term support in adult patients with severe left ventricular heart failure. It can be used while waiting for a heart transplant, to help the heart recover, or as a permanent solution when a transplant isn’t an option. HeartMate 3 can also be used in pediatric patients.

Both devices work by taking over the pumping function of the left ventricle, the main pumping chamber of the heart. They divert blood from the weakened left ventricle and propel it into the body’s main artery, the aorta, helping to circulate blood throughout the body. The devices are used both inside and outside of the hospital.

Reason for recall
Abbott/Thoratec Corp. is recalling HeartMate II and HeartMate 3 Left Ventricular Assist System (LVAS) due to an issue called Extrinsic Outflow Graft Obstruction, (EOGO). This happens when biological material builds up between the HeartMate Outflow Graft and the Outflow Graft Bend relief or additional components added during surgery. This buildup can obstruct the device, making it less effective in helping the heart pump blood. It can trigger alarms indicating low blood flow and affect the device’s ability to help the heart properly. The accumulation of biological material typically occurs over two years or more.

The use of affected LVAS may cause serious adverse health consequences and in worst cases, could result in death.

There have been 273 reported injuries and 14 reports of death associated with this issue.

Who may be affected

• Healthcare Professionals using the HeartMate II and HeartMate 3 Left Ventricular Assist Systems (LVAS) to provide care.
• People receiving care through either the HeartMate II or HeartMate 3 Left Ventricular Assist Systems (LVAS)

U.S. Food and Drug Administration